Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ) from its SEC filings: 2025 revenue $4.3 billion (+5% vs the year before), net margin -8%, free cash flow $1.3 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $4.3 billion |
| Revenue growth | +5% |
| Net income | -$356.1 million |
| Net margin | -8.3% |
| Free cash flow | $1.3 billion |
| Diluted EPS | $-5.84 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +16% |
| Cash | $1.6 billion |
| Long-term debt | $3.3 billion |
| Share count, 1 year | +7% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.